Canakinumab Clinical Trials
7 recruitingDrug
Phase 25Phase 32Phase 11
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center76 enrolled1 locationNCT04239157
Recruiting
Phase 2
Study of Canakinumab in Patients With Myelofibrosis
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting
Phase 2
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Clonal Cytopenia of Undetermined Significance
Uma Borate110 enrolled6 locationsNCT05641831
Recruiting
Phase 2
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Lung CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+10 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04789681
Recruiting
Phase 2Phase 3
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Skin InflammationAllergic Contact Dermatitis
Wei-Che Ko45 enrolled1 locationNCT05535738
Recruiting
Phase 1
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
Pancreatic Cancer
NYU Langone Health10 enrolled3 locationsNCT05984602
Recruiting
Phase 3
Canakinumab for the Treatment of Postprandial Hypoglycemia
Postprandial Hypoglycemia
University Hospital, Basel, Switzerland56 enrolled2 locationsNCT05401578